Last €10.50 EUR
Change Today +0.01 / 0.10%
Volume 582.0
ALVXM On Other Exchanges
Symbol
Exchange
EN Paris
As of 3:35 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

vexim sa (ALVXM) Snapshot

Open
€10.42
Previous Close
€10.49
Day High
€10.50
Day Low
€10.42
52 Week High
10/1/14 - €12.10
52 Week Low
01/16/14 - €9.40
Market Cap
61.8M
Average Volume 10 Days
7.3K
EPS TTM
--
Shares Outstanding
5.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VEXIM SA (ALVXM)

Related News

No related news articles were found.

vexim sa (ALVXM) Related Businessweek News

No Related Businessweek News Found

vexim sa (ALVXM) Details

Vexim SA, a medical device company, designs and markets minimally invasive solutions for the treatment of traumatic spinal pathologies. The company markets the SpineJack, an implant capable of repairing a deformed or fractured vertebra and restoring the anatomy of the spinal column. It also offers vertebroplasty therapy products comprising cement injection kit; Cohesion, a biocompatible high viscosity bone cement for pathological fracture; and Interface, a bone composite for traumatic fracture. The company sells its products through its sales teams in France, Germany, Italy, Spain, Switzerland, and the United Kingdom, as well as through distributors in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Chile, Panama, Mexico, Brazil, Venezuela, Ecuador, and Peru. Vexim SA is headquartered in Balma, France.

50 Employees
Last Reported Date: 04/29/14

vexim sa (ALVXM) Top Compensated Officers

Chief Executive Officer and Managing Director
Total Annual Compensation: €273.0K
Chairman and President
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

vexim sa (ALVXM) Key Developments

VEXIM to Initiate Clinical Study to Support its Application for 510(K) Regulatory Clearance to Market SpineJack in the U.S

VEXIM announced it will initiate a new clinical study that will support its planned application for 510(k) regulatory clearance to market SpineJack in the U.S. The company expects to complete the study in 2 years time in support of a 510(k) submission in 2017. The company will conduct a prospective multicenter, randomized study that will compare the safety and effectiveness at one year follow-up of the New Generation SpineJack device with Medtronic's balloon on 150 patients suffering from vertebral compression fractures due to osteoporosis.

Vexim Announces Six Month Results of Comparative Study of SpineJack Versus Balloon Kyphoplasty

Vexim announced the positive preliminary results at six months of an investigator-initiated study comparing the safety and performances of SpineJack to the Medtronic balloon in the treatment of vertebral compression fractures in patients with osteoporosis. These two devices are differently composed but achieve the same purpose. This pilot feasibility study was initiated by Dr. David Noriega, of the Hospital Clinico Universitario in Valladolid, Spain, supported by the company and after receiving approval from the hospital's Ethical Committee to treat 30 patients. Of the 30 patients, 15 were treated with SpineJack and 15 were treated with the Medtronic balloon. Patients were monitored post implantation and results were assessed at six months and will be reassessed at twelve months. The Company reported it has confirmed excellent near-term outcomes with SpineJack compared to the Medtronic balloon at six months post implantation. Patient groups treated with SpineJack achieved: Near-perfect restoration of vertebral height (evolution of anterior vertebral angle ratio: pre-op/post op from 71% to 76% for the balloon and from 66% to 82% for SpineJack), as well as perfect restoration of the physiological angle of the spine (evolution of the treated vertebra angle pre-op/postop: 5.4 degrees for Spinejack compared to 1.7 degrees for the balloon). A strong and rapid decline in pain (92% at six months for SpineJack compared to 81% for the balloon); A significantly shorter intervention period (23 minutes) compared with the balloon (32 minutes); No serious device-related adverse events, and it was not necessary to re-operate on any of the treated vertebrae.

Vexim SA Announces Consolidated Earnings Results for the First Half Ended June 30, 2014

Vexim SA announced consolidated earnings results for the first half ended June 30, 2014. For the period, the company reported sales of EUR 4,918,000 compared with EUR 2,533,000 for the same period a year ago. Operating loss was EUR 3,658,000 compared with EUR 4,130,000 for the same period a year ago. Net loss was EUR 3,674,000 compared with EUR 4,086,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALVXM:FP €10.50 EUR +0.01

ALVXM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Globus Medical Inc $19.56 USD -0.07
NuVasive Inc $34.51 USD -0.20
Stryker Corp $80.28 USD +1.08
Synthesis Energy Systems Inc $0.98 USD +0.0085
Zimmer Holdings Inc $97.52 USD +1.57
View Industry Companies
 

Industry Analysis

ALVXM

Industry Average

Valuation ALVXM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.4x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VEXIM SA, please visit www.vexim.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.